Across TCGA pan-cancer cohorts, TRAV36DV7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAV36DV7 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRAV36DV7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV36DV7 expression acts as an unfavorable survival marker.

LUAD, PRAD, and SKCM are the cancer types where TRAV36DV7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.338	0.834	.004	12	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRAV36DV7 tumor-vs-normal RNA expression · all TRAV36DV7 data types